Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alphamab Oncology ( (HK:9966) ) has issued an announcement.
Alphamab Oncology announced the grant of share options under its Post-IPO Share Option Scheme and award shares under the Restricted Share Award Scheme to eligible employees. This initiative is part of the company’s strategy to incentivize and retain talent, aligning employee interests with company performance and potentially enhancing its competitive positioning in the oncology sector.
More about Alphamab Oncology
Alphamab Oncology is a biopharmaceutical company focused on the development and commercialization of innovative cancer therapies. The company operates in the oncology sector, providing targeted treatments to address unmet medical needs in the cancer treatment market.
YTD Price Performance: 98.86%
Average Trading Volume: 5,352,525
Technical Sentiment Signal: Sell
Current Market Cap: HK$6.72B
Find detailed analytics on 9966 stock on TipRanks’ Stock Analysis page.